Loading
companiesCompany
Allogene Therapeutics
Allogeneic CAR-T leader: cema-cel (CD19) as MRD-guided first-line consolidation in lymphoma, and ALLO-316 (CD70) with responses in kidney cancer.
Overview
Allogene Therapeutics, based in South San Francisco and listed as ALLO, is the allogeneic CAR-T leader, with cema-cel, a CD19 CAR-T, positioned as MRD-guided first-line consolidation in lymphoma and ALLO-316, a CD70 CAR-T, showing responses in kidney cancer. Cema-cel received RMAT and Fast Track designations in July 2026 for MRD-positive large B-cell lymphoma after first-line therapy in the ALPHA3 trial, ALLO-316 gave a 31 percent confirmed response rate in CD70-high clear-cell renal cell carcinoma in the TRAVERSE trial in 2025. OnCo links it to diffuse large B-cell lymphoma and renal cell carcinoma, to allogeneic cell therapy, to CD19 and CD70 as targets and to the UCART19 paper. Whether treating MRD-positive patients before relapse improves outcomes is the question ALPHA3 will answer. Manufacturing cost and time is the bottleneck off-the-shelf cells are meant to relieve.
Headquarters
South San Francisco, CA, US
Scorecard
All companies#408of 1244 companies, score 8
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 1 targets, 3 registry studies. Formula on the scorecards page.
Type
Cell therapy · ALLO
Stage
Public
Website
Phase 2monoclonal antibody
ALLO-647 is an experimental monoclonal antibody from Allogene Therapeutics in phase 2 trials for diffuse large B-cell lymphoma, aimed at CD52.
Similar pages
- CompanyCaribou Biosciences
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19.
- CompanyFate Therapeutics
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19.
- CompanyCentury Therapeutics
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
- IdeaPlan the second CAR-T target before the first one is lost
Shares Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19, Minimal / molecular residual disease (MRD).
- PersonWaseem Qasim
Shares UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL, Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- PersonPolina Stepensky
Shares Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
- CompanyCellogen Therapeutics
Shares Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
cancers
fronts
technologies
targets
drugs
Phase 2monoclonal antibody